Pursuant to NASD Rule 2711(h)(6) and NYSE Rule 472(k)(i)(h), please click on the ticker for the latest pricing chart available for the subject company that depicts price target and rating revisions.
The information provided herein and via the BlueMatrix weblink shall not be deemed an offer or solicitation on our part with respect to the sale or purchase of any securities. Additionally, the limited information provided herein and via the BlueMatrix weblink is not sufficient and shall not be construed as sufficient information upon which a reasonable investor could make an investment decision. Broadpoint Capital research is intended for Institutional Investors. Research reports are available through your Broadpoint Capital Registered Representative. Should you have any specific investment questions, please contact your Broadpoint
Capital Registered Representative.
| Sector | Industry | Analyst |
| Technology | Advanced Materials | Avinash Kant, Ph.D. |
| Healthcare | Biotechnology | Simos Simeonidis, Ph.D. |
| Healthcare | Biotechnology | David Webber |
| Energy | Clean Technology | Colin Rusch |
| Energy | Cleantech / Biofuels | Ronald A. Oster |
| Technology | Enterprise Software | Bradley G. Whitt |
| Energy | Exploration and Production | Thomas Covington |
| Healthcare | Global Specialty Pharmaceuticals | David Lickrish, CFA |
| Healthcare | Healthcare Services | Glenn Garmont |
| Technology | Semiconductor Capital Equipment and Semiconductor Companies | Gavin Duffy |
<< Back to Research Overview
Transparency of Analysts' Performance
Broadpoint's rating system.
Learn More